| Cambridge Eye Group Inc | |
|
603 Concord Ave, Suite B, Cambridge, MA 02138-1197 | |
| (617) 818-0476 | |
| Not Available |
| Full Name | Cambridge Eye Group Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 603 Concord Ave, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235688557 | NPI | - | NPPES |
| Provider Name | Kit Tung Ip |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1972768075 PECOS PAC ID: 3476615121 Enrollment ID: I20081215000528 |
News Archive
A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.
The Northwest's leading deafness charity Deafness Support Network, has welcomed David Cameron's recent announcement of planned reforms to GP surgeries, suggesting it could change the lives of more than ten million people in the UK who are deaf or hard of hearing.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.
› Verified 1 days ago
| Provider Name | Jacky Kong |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1851556021 PECOS PAC ID: 1658425467 Enrollment ID: I20090813000198 |
News Archive
A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.
The Northwest's leading deafness charity Deafness Support Network, has welcomed David Cameron's recent announcement of planned reforms to GP surgeries, suggesting it could change the lives of more than ten million people in the UK who are deaf or hard of hearing.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.
› Verified 1 days ago
| Provider Name | Bonnie Quach |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1114662913 PECOS PAC ID: 3072995844 Enrollment ID: I20220727001455 |
News Archive
A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.
The Northwest's leading deafness charity Deafness Support Network, has welcomed David Cameron's recent announcement of planned reforms to GP surgeries, suggesting it could change the lives of more than ten million people in the UK who are deaf or hard of hearing.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.
› Verified 1 days ago
| Provider Name | Liqun Yuan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1477328391 PECOS PAC ID: 4688025448 Enrollment ID: I20240105003736 |
News Archive
A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.
The Northwest's leading deafness charity Deafness Support Network, has welcomed David Cameron's recent announcement of planned reforms to GP surgeries, suggesting it could change the lives of more than ten million people in the UK who are deaf or hard of hearing.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cambridge Eye Group Inc 169 Monsignor Obrien Hwy, 415, Cambridge, MA 02141-1289 Ph: () - | Cambridge Eye Group Inc 603 Concord Ave, Suite B, Cambridge, MA 02138-1197 Ph: (617) 818-0476 |
News Archive
A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.
The Northwest's leading deafness charity Deafness Support Network, has welcomed David Cameron's recent announcement of planned reforms to GP surgeries, suggesting it could change the lives of more than ten million people in the UK who are deaf or hard of hearing.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.
› Verified 1 days ago
Harvard Square Eye Care P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 19 Dunster St, Cambridge, MA 02138 Phone: 617-354-5590 | |
Cheryl Depalo A Jost, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1 Porter Sq, Cambridge, MA 02140 Phone: 617-864-7005 | |
Eyecare Associates Of Ma, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 56 Jfk St, Cambridge, MA 02138 Phone: 781-337-0674 Fax: 781-337-0285 | |
Central Square Eye Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3 Central Sq, Cambridge, MA 02139 Phone: 617-497-2015 | |
Amy Lee Cuomo, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 19 Dunster St, Cambridge, MA 02138 Phone: 617-354-5590 | |
Robert B Gross, OD Optometrist Medicare: Medicare Enrolled Practice Location: 77 Mass Ave, Medical E23-2s, Cambridge, MA 02139 Phone: 617-253-4351 |